My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 722

    1.

    Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

    Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.

    Diabetes. 2004 May;53(5):1187-94.PMID: 15111485 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

    Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB.

    Diabetes. 2003 Jul;52(7):1786-91.PMID: 12829647 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

    Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

    Diabetes Care. 1997 Dec;20(12):1874-9.PMID: 9405910 [PubMed - indexed for MEDLINE]Related articles

    5.

    Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

    Diabetes. 2001 Aug;50(8):1778-84.PMID: 11473038 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

    Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.

    Diabetes. 2001 Apr;50(4):776-84.PMID: 11289042 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.

    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.

    Diabetes Care. 1996 Aug;19(8):857-63.PMID: 8842604 [PubMed - indexed for MEDLINE]Related articles

    8.

    Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

    Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.

    Exp Clin Endocrinol Diabetes. 1998;106(2):103-7.PMID: 9628239 [PubMed - indexed for MEDLINE]Related articles

    9.

    Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

    Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

    Diabetologia. 1996 Dec;39(12):1546-53.PMID: 8960841 [PubMed - indexed for MEDLINE]Related articles

    10.

    Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

    Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.

    Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.

    Clin Sci (Lond). 1998 Sep;95(3):325-9.PMID: 9730852 [PubMed - indexed for MEDLINE]Related articles

    12.

    Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

    Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

    Diabetes Care. 2004 Jun;27(6):1335-42.PMID: 15161785 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

    Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25.PMID: 12788879 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

    Toft-Nielsen MB, Madsbad S, Holst JJ.

    Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

    DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L.

    Curr Med Res Opin. 2008 Oct;24(10):2943-52. Epub 2008 Sep 10.PMID: 18786299 [PubMed - indexed for MEDLINE]Related articles

    16.

    Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

    Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

    Diabetes Care. 2002 Dec;25(12):2147-52.PMID: 12453952 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

    Larsen J, Hylleberg B, Ng K, Damsbo P.

    Diabetes Care. 2001 Aug;24(8):1416-21.PMID: 11473079 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.

    Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.

    Diabetes Care. 2008 Jan;31(1):30-5. Epub 2007 Oct 18.PMID: 17947341 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

    Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA.

    J Clin Endocrinol Metab. 1996 Jan;81(1):327-32.PMID: 8550773 [PubMed - indexed for MEDLINE]Related articles

    20.

    Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects.

    Elbrønd B, Jakobsen G, Larsen S, Agersø H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M.

    Diabetes Care. 2002 Aug;25(8):1398-404.PMID: 12145241 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity